Clinical Trial Update: Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating mogamulizumab (KW-0761) in previously treated peripheral T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• KW-0761 (Mogamulizumab) (mogamulizumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Peripheral T-Cell Lymphoma | Phase 2 | Status: COMPLETED